ストックスクリーナーアプリを入手
4.62
0.65%
0.03
アフターアワーズ：
4.62
前日終値:
$4.59
開ける：
$4.59
24時間の取引高:
217.11K
Relative Volume:
1.13
時価総額：
$261.27M
収益：
$34.16M
当期純損益:
$-98.43M
株価収益率:
-1.9744
EPS:
-2.34
ネットキャッシュフロー:
$-119.33M
1週間 パフォーマンス:
-1.49%
1か月 パフォーマンス:
+13.51%
6か月 パフォーマンス:
+13.79%
1年 パフォーマンス:
-40.16%
1日の値動き範囲:
$4.54
$4.89
1週間の範囲:
$4.54
$5.685
52週間の値動き範囲:
$2.9448
$8.445
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
名前
Foghorn Therapeutics Inc
セクター
電話
617-586-3100
住所
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.62 | 259.57M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 再開されました | B. Riley Securities | Buy |
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 開始されました | B. Riley Securities | Buy |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-08-19 | 開始されました | Evercore ISI | Outperform |
| 2023-03-28 | 開始されました | BofA Securities | Buy |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-17 | 開始されました | Cowen | Outperform |
| 2020-11-17 | 開始されました | Goldman | Buy |
| 2020-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-17 | 開始されました | Wedbush | Outperform |
すべてを表示
Foghorn Therapeutics Inc (FHTX) 最新ニュース
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewswire Inc.
Applying big data sentiment scoring on Foghorn Therapeutics Inc.Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Why Foghorn Therapeutics Inc. stock could outperform in 2025July 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com
How risky is Foghorn Therapeutics Inc. stock now2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-15 18:34:42 - newser.com
Volatility clustering patterns for Foghorn Therapeutics Inc.July 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
Will Foghorn Therapeutics Inc. stock maintain growth story2025 Technical Overview & Weekly Consistent Profit Watchlists - Fundação Cultural do Pará
Foghorn Therapeutics Unveils Strategic Advancements with Lilly - MSN
Momentum divergence signals in Foghorn Therapeutics Inc. chartJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Foghorn Therapeutics Incon Oct 31, Kristian Humer resigned as CFO effective November 14, 2025SEC filing - MarketScreener
Foghorn Therapeutics Inc (FHTX) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):